Organisation paid for research Program year 2025 Source: CMS Open Payments

North Texas Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$1,417,033

54 payments

Through program year 2025, North Texas Clinical Trials LLC is reported as receiving $1,417,033 in research payments, across 54 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $376,613 22
2024 Research $394,336 13
2023 Research $422,431 3
2022 Research $127,955 4
2019 Research $95,698 12

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sage Therapeutics, Inc. $802,669 9 payments
  2. Janssen Research & Development, LLC $299,807 25 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $204,860 6 payments
  4. Allergan Inc. $95,698 12 payments
  5. ITI, Inc. $14,000 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Study to Evaluate SAGE-324 in Participants With Essential Tremors $458,641 3 payments
  2. A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor $298,668 3 payments
  3. A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso $210,449 16 payments
  4. BI 425809 Pivotal efficacy study 1 $116,186 2 payments
  5. A Randomized, Double-Blind, Placebo Controlled, Multicenter Study of Rapastinel As Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder $84,692 11 payments
  6. A Randomized, Stratified, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of JNJ-55308942 in Bipolar Depression $65,984 6 payments
  7. Study to Evaluate Sage-324 in Participants With Essential Tremors $45,360 3 payments
  8. Connex-X $42,606 1 payment
  9. Connex 1 $40,987 2 payments
  10. A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms $23,374 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record